MucofanTM
MucofanTM
A probiotic lozenge with Lactobacillus brevis CD2 that helps prevent and reduce oral mucositis in patients undergoing radiotherapy, chemotherapy, or Hematopoietic Stem Cell Transplantation (HSCT).
What It Does
- Helps prevent oral mucositis when started before cancer therapy
- Helps treat existing lesions, reducing pain and inflammation
- Improves treatment tolerance and overall Quality of Life (QoL)
- Supports continuity of radiotherapy/chemotherapy without interruptions
MUCOFAN™ - Composition
- Each lozenge contains ≥ 2 billion CFU of Lactobacillus brevis CD2
- Available as lozenges / chewable tablets
How It Works
- Contains Lactobacillus brevis CD2 enriched with Arginine Deiminase activity
- Reduces nitric oxide and polyamine levels → lower inflammation
- Helps maintain mucosal integrity during cancer treatment
Indications
- Radiotherapy-induced oral mucositis
- Chemotherapy-induced oral mucositis
- Supportive care during HSCT
FAQs
What is MUCOFAN™?
A probiotic lozenge that helps prevent and reduce oral mucositis during cancer treatment.
How does MUCOFAN™ help patients?
It reduces inflammation in the mouth, easing pain and speeding recovery.
When should MUCOFAN™ be used?
Ideally before starting radiotherapy or chemotherapy and continued during treatment.
Is MUCOFAN™ safe?
Yes — it is well-tolerated and safe for adults undergoing cancer therapy.
How is MUCOFAN™ taken?
As easy-to-use lozenges or chewable tablets for direct action on oral tissues.
What makes MUCOFAN™ different?
Its unique CD2 strain delivers strong anti-inflammatory benefits backed by clinical evidence.